Clinical Research Directory
Browse clinical research sites, groups, and studies.
Multiparametric Metabolic and Hypoxic PET/MRI Imaging Substudy in Gliomas
Sponsor: University of Alabama at Birmingham
Summary
This substudy will investigate a new imaging approach using positron emission tomography (PET) and two investigational drugs (\[18F\]FET and \[18F\]FMISO) to see if the imaging results will help with the placement of catheters for therapy delivery in 20 adult patients with malignant gliomas (MGs) who are participating in the UAB IRB approved main study, A Phase I/II Study of Pembrolizumab and M032 (NSC 733972), a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive and Newly Diagnosed Glioblastoma Multiforme, grade 3 or grade 4 astrocytoma, or Gliosarcoma (IRB 300007756 PI Markert). The PET and MR imaging results will be available to guide catheter placement within IRB 300007756 study-specific guidelines during Neurosurgery.
Official title: Multiparametric Metabolic and Hypoxic PET/MRI Imaging Substudy for Disease Assessment and Guidance of Catheters in Patients With Recurrent/Progressive Malignant Gliomas Eligible for Catheter-delivered Therapies
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2026-09
Completion Date
2030-11
Last Updated
2026-08-24
Healthy Volunteers
No
Conditions
Interventions
[18F]FMISO-PET with contrast-enhanced MRI
Glioma patients enrolled in the main study (IRB 300007756) will complete 4 to 5 imaging visits. Visit 1 will take place prior to participants scheduled surgery. Visit 1 could be two seperate imaging visits between \[18F\]FMISO and \[18F\]FET, if needed. Participants will have three additional \[18F\]FET PET/MRIs at 1 month, 3 months and 6 months post-surgery.
Locations (1)
UAB
Birmingham, Alabama, United States